Evonik and Higuchi Launch Joint Lab for Oral Drug Delivery in Japan

Evonik and Higuchi Inc., a Japanese pharmaceutical trading company, are launching a joint laboratory, “Open Pharma Lab,” in Yokohama, Japan, opening on May 1. The facility will provide local formulators with hands-on access to Evonik’s EUDRAGIT® polymers and formulation expertise to support the development of patient-centric oral dosage forms, while further strengthening Evonik’s regional innovation network across Asia.

Evonik's head of Health Care business line Guido Skudlarek said "We are delighted to deepen our long‑standing partnership with Higuchi and support the Japanese pharmaceutical industry with integrated system solutions built around EUDRAGIT®, one of the most trusted technologies in oral drug delivery. By bringing our complementary strengths together in the Open Pharma Lab, we aim to accelerate innovation and help customers advance their product development"

EUDRAGIT® polymers are widely recognized excipient technologies for oral drug delivery, valued for their versatility and regulatory acceptance. They enable precise control over drug release while supporting the development of stable, patient-friendly solid dosage forms. Evonik complements this portfolio with integrated system solutions that combine advanced materials, formulation science, and application expertise to help pharmaceutical companies address complex development challenges efficiently.

The Open Pharma Lab further strengthens Evonik’s long-standing presence in Japan by expanding access to EUDRAGIT® polymers and technical services. Through collaborative formulation support, tailored technical assistance, and access to Evonik’s global drug delivery expertise, the facility aims to accelerate development timelines and support innovative oral drug products designed for regional needs.

President & CEO of Higuchi Inc Wataru Ohama said "The establishment of this joint lab with Evonik is an important step toward providing advanced technical support to our customers. By maximizing the potential of EUDRAGIT®, we aim to help drive innovation and contribute to the continued growth of Japan’s pharmaceutical market".

Source: Evonik